TRANSFORM Heart Failure with Reduced Ejection Fraction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-22

Study Completion Date

2024-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of the TRANSFORM-HFrEF trial will be to study the current guideline-directed medical therapy (GDMT) landscape for HFrEF and determine effective methods and models of increasing adherence to GDMT and improving Quality of Life (QOL) in outpatient settings within the context of the 20-minute visit. This will be achieved through a randomized evaluation that shifts standard clinical interview and documentation requirements outside the office visit and building the patient and physician relationship through trust and shared goal setting.

Specific Aims:

To evaluate the ability of ACC Solution Sets and Patient Resources to improve initiation and titration of GDMT for eligible patients with HFrEF Left Ventricle Ejection Fraction (LVEF) ≤ 40%.

To evaluate change in QOL between patients in the intervention arm and the Usual Care arm.

Examine the relative change in GDMT among higher risk versus lower-risk patients in the Intervention arm and Usual Care arm.

In this randomized registry trial, sites will be invited to participate in a 6-month study aimed at various processes of care in HFrEF. Sites would be informed that they might be asked to participate in an intensive intervention to improve GDMT prescription or in a study of QOL in HFrEF. Once a list of sites interested in participating is created, sites would be randomized into two arms: an intervention group and a usual care group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction

NCT05637853

Heart Failure With Reduced Ejection Fraction

ACTIVE_NOT_RECRUITING PHASE4

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

NCT03296813

Heart Failure

COMPLETED PHASE3

Tailored Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients With Heart Failure

NCT06847438

Heart Failure

RECRUITING NA

The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients

NCT05858320

Heart Failure

COMPLETED PHASE3

Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction

NCT06517186

Heart Failure Heart Failure With Preserved Ejection Fraction

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Heart Failure (HF) is the cardiovascular epidemic of the 21st century, affecting millions of patients worldwide. It is believed that HF is the only cardiovascular diagnosis rising in incidence among elderly patients and is the #1 diagnosis leading to hospitalization among Medicare recipients. In addition to being increasingly prevalent, HF has a poor outlook after initial diagnosis and is associated with poor quality of life (QOL) in affected patients; this not only leads to the burden on patients, family, and other caregivers but also on the healthcare system. For all these reasons, optimizing the understanding and care of patients with HF is a major priority.

Although clinical practice guidelines clearly articulate optimal GDMT for the care of patients with HFrEF, implementation of GDMT into the management of such patients has proven to be suboptimal, with most patients under-treated relative to goal therapy.

To evaluate the contemporary status of GDMT delivery for HFrEF, the recent Change the Management of Patients with Heart Failure (CHAMP-HF) registry included 3518 patients from 150 primary care and cardiology practices (1,2). The mean age of this cohort was 66 ± 13 years, 29% were female, and mean EF was 29 ± 8%, thus representing a very characteristic population of patients with HFrEF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure, Systolic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Usual Care Arm

Will not use HealthReveal to titrate the doses of Entresto/ other treatments for HFrEF.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventional- Health Reveal

The interventional arm will be provided tools to augment quality of care and build the patient and physician relationship through trust and shared goal-setting.

Prior to each patient appointment, on a customized GDMT Dashboard, the site will receive a pre-visit assessment of GDMT accompanied by recommended adjustment(s) using information extracted weekly from the sites' electronic health record (EHR). The recommended adjustment(s) will be conveyed using proprietary software from HealthReveal, with a suggested follow up plan. All reminders regarding dosing targets are based on the 2020 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment.

Additionally, during visits at baseline, 3 months, and 6 months, patient-reported outcomes/QOL will be assessed.

Group Type EXPERIMENTAL

HealthReveal

Intervention Type OTHER

In the Intervention arm, for each study visit, the site will receive a pre-visit assessment of GDMT accompanied by recommended adjustment(s) using information extracted weekly from the sites' EHR.

The recommended adjustment(s) will be conveyed using proprietary software from HealthReveal, with a suggested follow up plan. All reminders regarding dosing targets are based on the 2020 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment.

Additionally, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed.

In the Usual Care arm, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HealthReveal

In the Intervention arm, for each study visit, the site will receive a pre-visit assessment of GDMT accompanied by recommended adjustment(s) using information extracted weekly from the sites' EHR.

The recommended adjustment(s) will be conveyed using proprietary software from HealthReveal, with a suggested follow up plan. All reminders regarding dosing targets are based on the 2020 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment.

Additionally, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed.

In the Usual Care arm, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years
* Clinical diagnosis of HF with EF ≤40% documented within 1 year of enrollment
* Receiving ≥1 oral medication for HF at study enrollment (including diuretics, ACEI/ARB/ARNI, beta-blockers, MRA, SGLT2i or thiazide diuretics.

Exclusion Criteria

* Current or anticipated participation in a clinical trial
* Currently receiving comfort care or enrolled in hospice
* Life expectancy \<1 year
* History of or plan for heart transplantation or left ventricular assist device
* Current or planned hemodialysis

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No